Appendix 3Y Change of Director's Interest Notice

Appendix 3Y

Rule 3.19A.2

For personal use only

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity

CARDIEX LIMITED

ABN

81 113 252 234

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the

director for the purposes of section 205G of the Corporations Act.

Name of Director

Craig Cooper

Date of last notice

25 October 2021

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or indirect interest

Direct & Indirect

Nature of indirect interest

C2 Ventures Pty Ltd

Note: Provide details of the circumstances giving rise to the

the securities held in this entity.

(including r g stered holder)

Craig Cooper is a co-beneficiary and controller of

relevant interest.

CooperativeHealth LLC

Craig Cooper is the sole beneficiary and controller

of the securities held in this entity.

Date of change

30 November 2021

+ See chapter 19 for defined terms.

Appendix 3Y Page 1

01/01/2011

Appendix 3Y

Change of Director's Interest Notice

No. of securities held prior to change

Direct Interests

•

68,000,000 Performance Rights

only

C2 Ventures Pty Ltd

•

197,242,010 FPO

•

17,500,000 unlisted options at $0.05

•

expiring 30 November 2021

234,944 Convertible Notes with face

•

value of $1

1,500,000

Options at $0.05 expiring 26

•

February 2024

use

4,420,455

CDXO at $0.05 expiring 30

November 2021

CooperativeHealth LLC

•

36,000,000 Performance Rights

Class

As above

personal

Number acquired

Direct Interest

(a)

6,000,000

FPO

C2 Ventures Pty Ltd

(b)

17,500,000 FPO

(c)

7,831,467

FPO

(d)

2,240,455

FPO

CooperativeHealth LLC

(e)

12,000,000 FPO

Number disposed

C2 Ventures Pty Ltd

(a)

17,500,000 unlisted options at $0.05

expiring 30 November 2021

(b)

234,944 Convertible Notes with face

value of $1

(c)

2,420,455

CDXO converted

(d)

2,000,000

CDXO transferred via off

For

market transfer

CooperativeHealth LLC

(e)

12,000,000 Performance Rights

exercised

(f)

6,000,000

FPO transferred to Niall

Cairns (or his nominee)

(g)

6,000,000

FPO transferred to Craig

Cooper's Direct Interest

(h)

8,000,000

Performance Rights expired

+ See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 2

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Note: If consideration is non-cash, provide details and

(a)

NIL

Value/Consideration

In respect of the acquisitions of securities:

estimated valuation

(b)

$0.05 per share

(c)

$0.03 per share

(d)

$0.05 per share

(e)

NIL

In respect of the disposals of securities:

(a)

N/A - conversion of unlisted options resulting

in acquisition of FPO (see (b) above)

(b)

N/A - conversion of convertible note resulting

in acquisition of FPO (see (c) above)

(c)

N/A - conversion of CDXO listed option

resulting in acquisition of FPO (see (d) above)

(d)

Nil consideration received - off-market sale of

CDXO listed options

(e)

Nil consideration received - exercise of

vested Performance Rights

(f)

Nil consideration received - transfer of FPO

received

on

conversion

of

vested

Performance Rights to Carnethy Investments

Pty Ltd (an entity controlled by Niall Cairns)

(g)

Nil consideration received - transfer of FPO

received

on

conversion

of

vested

Performance Rights from CooperativeHealth

LLC to Craig Cooper

(h)

N/A - Performance rights cancelled on expiry

No. of securities held after change

Direct Interests

•

68,000,000 Performance Rights

•

6,000,000 FPO

C2 Ventures Pty Ltd

• 224,993,932 FPO

• 1,500,000 Options at $0.05 expiring 26 February 2024

CooperativeHealth LLC

• 16,000,000 Performance Rights

+ See chapter 19 for defined terms.

Appendix 3Y Page 3

01/01/2011

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Example: on-market trade, off-market trade, exercise of

(a)

Transfer from Craig Cooper's indirect to

Nature of change

In respect of the acquisitions of securities:

options, issue of securities under dividend reinvestment plan,

direct interest

participation in buy-back

(b)

Exercise of unlisted options

(c)

7,831,467 shares issued on conversion of

Convertible Notes at $0.03 per share

(d)

Exercise of CDXO

(e)

Vesting of performance rights

In respect of the disposals of securities:

  1. conversion of unlisted options resulting in acquisition of FPO
  2. conversion of convertible note resulting in acquisition of FPO
  3. conversion of CDXO listed option resulting in acquisition of FPO
  4. off-marketsale of CDXO listed options
  5. exercise of vested Performance Rights
  6. off-markettransfer of FPO received on conversion of vested Performance Rights to Carnethy Investments Pty Ltd (an entity controlled by Niall Cairns)
  7. off-markettransfer of FPO received on conversion of vested Performance Rights from CooperativeHealth LLC to Craig Cooper
  8. Performance rights cancelled on expiry

Part 2 - Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract

N/A as no interest in contracts

Nature of interest

N/A

Name of registered holder

N/A

(if issued securities)

Date of change

N/A

No. and class of securities to which

N/A

Note: Details are only required for a contract in

interest related prior to change

relation to which the interest has changed

Interest acquired

N/A

Interest disposed

N/A

Note: If consideration is non-cash, provide details and

Value/Consideration

N/A

an estimated valuation

Interest after change

N/A

+ See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 4

For personal use only

Appendix 3Y

Change of Director's Interest Notice

Part 3 - +Closed period

Were the interests in the securities or

In respect of the off-market transfer of CDXO

contracts detailed above traded during a

listed options, and the off-market transfers of

+closed period where prior written

FPO between CooperativeHealth LLC, Carnethy

clearance was required?

Investments Pty Ltd and Craig Cooper, the

securities were not traded during a closed

period.

All other transactions were not trades of

securities so N/A in all other respects.

If so, was prior written clearance

N/A

provided to allow the trade to proceed

during this period?

If prior written clearance was provided,

N/A

on what date was this provided?

+ See chapter 19 for defined terms.

Appendix 3Y Page 5

01/01/2011

This is an excerpt of the original content. To continue reading it, access the original document here.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Cardiex Limited published this content on 09 December 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 December 2021 23:01:05 UTC.